|Articles|September 4, 2009

ERT Celebrates TET Milestone

ERT (Philadelphia, PA) is celebrating what it describes as a significant milestone: The completion of its 150th Thorough QT clinical trial (TET).

“The TET study plays a crucial role in the development of a new pharmaceutical product," said John Blakeley, executive vice president of ERT, in a company press release. "We are very excited to have supported the industry to help improve the cardiac safety of new drugs coming to market."

With the advent of the ICH E14 Guidance in 2005, a TET has become a necessary part of the trials process for most drugs that require rigorous and robust electrocardiographic testing (ECG).


Related to this article

The Next Evolution of Patient-Centered Trials Starts with Design
Decentralized trial success depends less on how far activities move away from sites than on matching each activity’s delivery model to participant burden, site readiness, and data integrity, using patient intelligence to decide where flexibility helps and where site-based care remains essential.
© putilov_denis - © putilov_denis - stock.adobe.com
Sponsors rigorously vet CROs for oncology expertise but rarely apply the same scrutiny to the IRB reviewing their trials, even though increasingly complex protocols require reviewers with substantive therapeutic knowledge, not just a rostered oncologist.